Nutriband Valuation

Is NTRB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NTRB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate NTRB's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate NTRB's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for NTRB?

Key metric: As NTRB is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for NTRB. This is calculated by dividing NTRB's market cap by their current revenue.
What is NTRB's PS Ratio?
PS Ratio29.3x
SalesUS$1.80m
Market CapUS$52.71m

Price to Sales Ratio vs Peers

How does NTRB's PS Ratio compare to its peers?

The above table shows the PS ratio for NTRB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2.9x
MRMD MariMed
0.3x8.1%US$57.2m
JUSH.F Jushi Holdings
0.3x8.7%US$66.6m
VRCA Verrica Pharmaceuticals
10.9x53.1%US$89.7m
CBST.F Cannabist Company Holdings
0.1x-0.5%US$52.9m
NTRB Nutriband
29.3xn/aUS$52.7m

Price-To-Sales vs Peers: NTRB is expensive based on its Price-To-Sales Ratio (29.3x) compared to the peer average (2.9x).


Price to Sales Ratio vs Industry

How does NTRB's PS Ratio compare vs other companies in the US Pharmaceuticals Industry?

70 CompaniesPrice / SalesEstimated GrowthMarket Cap
OGN Organon
0.6x-0.06%US$4.16b
PRGO Perrigo
0.9x3.4%US$3.87b
BHC Bausch Health Companies
0.3x1.5%US$2.92b
AMRX Amneal Pharmaceuticals
1x5.6%US$2.60b
NTRB 29.3xIndustry Avg. 2.9xNo. of Companies70PS048121620+
70 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: NTRB is expensive based on its Price-To-Sales Ratio (29.3x) compared to the US Pharmaceuticals industry average (2.9x).


Price to Sales Ratio vs Fair Ratio

What is NTRB's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NTRB PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio29.3x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate NTRB's Price-To-Sales Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies